XML 53 R36.htm IDEA: XBRL DOCUMENT
v3.25.4

Common Stock, Stock Options, Restricted Stock Awards, and Warrants - Schedule of Assumptions were used in determining the Fair Value of Stock Option (Details) | Sep. 30, 2025 | Sep. 30, 2024
--- | --- | ---
Stock Option Grants [Member] | Risk-Free Interest Rate [Member] | Minimum [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 4.17 | 4.62
Stock Option Grants [Member] | Risk-Free Interest Rate [Member] | Maximum [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 4.31 | 4.66
Stock Option Grants [Member] | Expected Dividend Yield [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 0 | 0
Stock Option Grants [Member] | Expected Term [Member] | Minimum [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 5.5 | 5.5
Stock Option Grants [Member] | Expected Term [Member] | Maximum [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 10 | 10
Stock Option Grants [Member] | Expected Volatility [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 85 |
Stock Option Grants [Member] | Expected Volatility [Member] | Minimum [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants |  | 85
Stock Option Grants [Member] | Expected Volatility [Member] | Maximum [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants |  | 86
Citius Oncology Stock Option Grants [Member] | Risk-Free Interest Rate [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants |  | 4.66
Citius Oncology Stock Option Grants [Member] | Risk-Free Interest Rate [Member] | Minimum [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 4.08 |
Citius Oncology Stock Option Grants [Member] | Risk-Free Interest Rate [Member] | Maximum [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 4.18 |
Citius Oncology Stock Option Grants [Member] | Expected Dividend Yield [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 0 | 0
Citius Oncology Stock Option Grants [Member] | Expected Term [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants |  | 6.5
Citius Oncology Stock Option Grants [Member] | Expected Term [Member] | Minimum [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 5.5 |
Citius Oncology Stock Option Grants [Member] | Expected Term [Member] | Maximum [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 6.5 |
Citius Oncology Stock Option Grants [Member] | Expected Volatility [Member] |  |
Schedule of Assumptions were used in determining the Fair Value of Stock Option [Line Items] |  |
Fair value of stock option grants | 85 | 87

X
- Definition Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_EquitySecuritiesFvNiMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 43 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_PlanNameAxis=ctxr_StockOptionGrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=ctxr_CitiusOncologyStockOptionGrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |